Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
CIPLA GEFITINIB, GEFTICIP, GEFTIRESS (Cipla Australia Pty Ltd)
Product name
CIPLA GEFITINIB, GEFTICIP, GEFTIRESS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
164 working days (255)
Active ingredients
gefitinib
Registration type
New generic medicine
Indication
CIPLA GEFITINIB, GEFTICIP, GEFTIRESS (film coated tablets) are indicated for the treatment of patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) whose tumours express activating mutations of the EGFR tyrosine kinase.